

Date: 01.09.2023

To,  
The Manager  
BSE Limited  
P. J. Towers, Dalal Street  
Mumbai-400001.

Dear Sir/ Madam,

**Sub: Outcome of Board Meeting held on 01.09.2023**

**Ref: Regulation 30 and 33 along with Schedule III of SEBI(LODR) Regulations, 2015**

With reference to the subject cited, this is to inform the exchanges that at the Board Meeting of Sangam Healthcare Products Limited held on Friday, 01.09.2023 at 04.00 P.M at the registered office of the company, approved the following items of business:

1. Un-Audited Financial results for the Quarter / Nine months ended 31.12.2022 (enclosed).
2. Limited Review Report for the quarter/nine months ended 31.12.2022. (enclosed)

The meeting concluded at 5.00 P.M.

This is for your information and records.

Thanking You,

For and on Behalf of the  
Sangam Healthcare Products Limited

  
A. Bala Gopal  
Chairman and Managing Director  
(DIN: 01702903)



**SANGAM HEALTH CARE PRODUCTS LIMITED**  
 205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD  
**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2022**

(Rs. In Lakhs)

Particulars	Quarter Ended			Year Ended
	31-12-2022 Un-Audited	30.09.2022 Un-Audited	31-12-2021 Un-Audited	31-03-2022 Audited
<b>1</b> Income from Operations				
(a) Net Sales/Income from Operations	295.12	297.15	370.58	870.43
(b) Other Income	-	-	6.90	-
<b>Total Income</b>	<b>295.12</b>	<b>297.15</b>	<b>377.48</b>	<b>870.43</b>
<b>2</b> Expenditure				
(a) Cost of Raw material consumed	149.47	115.66	309.04	592.86
(b) Purchase of stock-in-trade	-	-	-	-
(c) Change in inventories of Finished Goods Works-in Progress and Stock in Trade	-	-	(30.22)	(61.34)
(d) Employees Benefit Expenses	83.84	86.54	97.22	201.65
(e) Depreciation and Amortization Expenses	30.43	30.43	27.56	121.72
(f) Other Expenditure	57.35	93.58	98.18	188.17
<b>Total expenses</b>	<b>321.10</b>	<b>326.21</b>	<b>501.78</b>	<b>1,043.04</b>
<b>3</b> Profit from Operations before Other Income, Financial Cost and Exceptional Items (1-2)	(25.98)	(29.06)	(124.30)	(172.61)
<b>4</b> Exceptional Items	-	-	-	-
<b>9 Profit / (Loss) from Ordinary Activities before tax (7+8)</b>	<b>(25.98)</b>	<b>(29.06)</b>	<b>(124.30)</b>	<b>(172.61)</b>
10 Current tax	0.82	0.72	-	11.17
Deferred tax	-	-	-	(17.87)
<b>11 Net Profit (+)/Loss(-) from Ordinary Activities After Tax (9-10)</b>	<b>(26.80)</b>	<b>(29.78)</b>	<b>(124.30)</b>	<b>(165.91)</b>
<b>12</b> Paid up equity share capital (no of shares) (face value of the share Rs.10/-)	1486.07	1486.07	1486.07	1,486.07
<b>13</b> Reserves excluding revaluation reserves	NIL	NIL	NIL	NIL
<b>14</b> Earning Per Share (EPS)	(0.0180)	(0.0200)	(0.0836)	(0.1116)
a) Basic and diluted Eps before Extraordinary (not to be annualized)				
b) Basic and diluted Eps after Extraordinary (not to be annualized)				

## Note :

- The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at the meeting held on 03.09.2023.
- 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Previous Accounting period's figures have been grouped/regrouped wherever considered necessary.

 Place : Hyderabad  
 Date : 01-09-2023

For Sangam Health Care Products Limited

  
 Chairman and Managing Director






**LIMITED REVIEW REPORT**

To,  
**The Board of Directors,**  
**SANGAM HEALTH CARE PRODUCTS LIMITED**

We have reviewed the accompanying statement of Un-audited Financial Results of **SANGAM HEALTH CARE PRODUCTS LIMITED** or the quarter ended **31<sup>st</sup> December, 2022** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.


This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 01-09-2023.

For **M M REDDY & CO.,**  
Chartered Accountants  
Firm Reg No.: 010371S

  
**M. Madhusudhana Reddy**  
Partner  
Membership No. 213077  
UDIN: 23213077BGTRQF6147

